{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:18:40Z","timestamp":1774477120062,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1010,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in patients hospitalized for acute HF with left ventricular ejection fraction &amp;lt;50% in the AFFIRM-AHF trial. We quantified the effect of FCM on burden of disease and the wider pharmacoeconomic implications in France, Germany, Poland, Spain and Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The per country eligible population was calculated, aligning with the 2021 European Society of Cardiology (ESC) HF guidelines and the AFFIRM-AHF trial. Changes in burden of disease with FCM versus standard of care (SoC) were represented by disability-adjusted life years (DALYs), hospitalization episodes and bed days, using AFFIRM-AHF data. A Markov model was adapted to each country to estimate cost-effectiveness and combined with epidemiology data to calculate the impact on healthcare budgets. Between 335 (Sweden) and 13\u2009237 (Germany) DALYs were predicted to be avoided with FCM use annually. Fewer hospitalizations and shorter lengths of stay associated with FCM compared to SoC were projected to result in substantial annual savings in bed days, from 5215 in Sweden to 205\u2009630 in Germany. In all countries, FCM was predicted to be dominant (cost saving with gains in quality-adjusted life years), resulting in net savings to healthcare budgets within 1\u2009year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This comprehensive evaluation of FCM therapy highlights the potential benefits that could be realized through implementation of the ESC HF guideline recommendations regarding ID treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2788","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T04:08:31Z","timestamp":1675138111000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Ferric Carboxymaltose for Iron Deficiency at Discharge After Heart Failure Hospitalization: A European Multinational Economic Evaluation"],"prefix":"10.1093","volume":"25","author":[{"given":"Phil","family":"McEwan","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cale","family":"Harrison","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhona","family":"Binnie","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Hospital Lariboisi\u00e8re, AP-HP, INSERM U948 MASCOT, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet and Heart and Vascular Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Malm\u00f6 University Hospital , Malm\u00f6 ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of G\u00f6ttingen Medical Center and German Center for Cardiovascular Research (DZHK) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari Bellvitge, University of Barcelona and IDIBELL , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo A.","family":"Pascual-Figal","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Virgen de la Arrixaca, University of Murcia, Murcia, Spain; and Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"W\u00e4chter","sequence":"additional","affiliation":[{"name":"CSL Vifor , Glattbrugg ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Dorigotti","sequence":"additional","affiliation":[{"name":"CSL Vifor , Glattbrugg ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Ramirez","family":"de Arellano","sequence":"additional","affiliation":[{"name":"HEOR, CSL Vifor , Glattbrugg ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa A.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, University Hospital , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"2026010913115661300_ejhf2788-bib-0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026010913115661300_ejhf2788-bib-0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/164_2017_27","volume-title":"Heart Failure","author":"van der Wal","year":"2017"},{"key":"2026010913115661300_ejhf2788-bib-0004","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026010913115661300_ejhf2788-bib-0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010913115661300_ejhf2788-bib-0006","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/heartjnl-2014-305669","article-title":"Iron deficiency: an emerging therapeutic target in heart failure","volume":"100","author":"Cohen-Solal","year":"2014","journal-title":"Heart"},{"key":"2026010913115661300_ejhf2788-bib-0007","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026010913115661300_ejhf2788-bib-0008","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":". Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026010913115661300_ejhf2788-bib-0009","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.1710","article-title":"Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure","volume":"21","author":"Ponikowski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/ejhf.2270","article-title":"Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF","volume":"23","author":"McEwan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0011","volume-title":"Global burden of disease study 2017 (GBD 2017) Disability Weights","author":"GHDx","year":"2017"},{"key":"2026010913115661300_ejhf2788-bib-0012","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ehf2.12432","article-title":"Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France","volume":"6","author":"Bourguignon","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ehf2.12179","article-title":"Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany","volume":"4","author":"Theidel","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0014","volume-title":"Estimaci\u00f3n de pesos y costes de los procesos hospitalarios en el Sistema Nacional de Salud: metodolog\u00eda y principales resultados. Proyecto 2017","author":"de Sanidad"},{"key":"2026010913115661300_ejhf2788-bib-0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2026010913115661300_ejhf2788-bib-0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026010913115661300_ejhf2788-bib-0017","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913115661300_ejhf2788-bib-0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.aprim.2022.102413","article-title":"Burden of heart failure in primary healthcare","volume":"54","author":"Gonzalez-Loyola","year":"2022","journal-title":"Aten Primaria"},{"key":"2026010913115661300_ejhf2788-bib-0019","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/14017431.2018.1546894","article-title":"Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries","volume":"52","author":"Hofmarcher","year":"2018","journal-title":"Scand Cardiovasc J"},{"key":"2026010913115661300_ejhf2788-bib-0020","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2217\/cer-2019-0074","article-title":"Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact","volume":"8","author":"Rognoni","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2026010913115661300_ejhf2788-bib-0021","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","article-title":"Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK","volume":"14","author":"Gutzwiller","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0022","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.recesp.2014.10.011","article-title":"A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain","volume":"68","author":"Com\u00edn-Colet","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026010913115661300_ejhf2788-bib-0023","doi-asserted-by":"crossref","first-page":"A392","DOI":"10.1016\/j.jval.2015.09.876","article-title":"Cost-effectiveness of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Austria","volume":"18","author":"Walter","year":"2015","journal-title":"Value Health"},{"key":"2026010913115661300_ejhf2788-bib-0024","volume-title":"WHO methods and data sources for global burden of disease estimates 2000-2019","author":"World Health Organization","year":"2020"},{"key":"2026010913115661300_ejhf2788-bib-0025","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study","volume":"42","author":"Jankowska","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913115661300_ejhf2788-bib-0026","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1838","article-title":"Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials","volume":"23","author":"von Haehling","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913115661300_ejhf2788-bib-0028","volume-title":"ISPOR 18th annual European congress","author":"Rossl","year":"2015"},{"key":"2026010913115661300_ejhf2788-bib-0029","first-page":"131","article-title":"Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Romania","volume":"5","author":"Lorenzovici","year":"2019","journal-title":"J Cardiovasc Emerg"},{"key":"2026010913115661300_ejhf2788-bib-0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/13696998.2020.1838872","article-title":"Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain","volume":"23","author":"Delgado","year":"2020","journal-title":"J Med Econ"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/3\/389\/65552363\/eurjhf_25_3_389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/3\/389\/65552363\/eurjhf_25_3_389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:15:01Z","timestamp":1767982501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/3\/389\/8343589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2788","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}